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Dear Editor,
Paracoccidioidomycosis (PCM) is a fungal disease, chronic and
endemic,  especially in Latin America.1 Aiming to acquire
more  information about the effectiveness of the treatment
employed, this study aimed to describe the proﬁles of patients
with  paracoccidioidomycosis and compare treatments used in
patients with PCM cared for at the Clinic of Tropical Medicine
of  the “Conjunto Hospitalar de Sorocaba” (CHS) regarding efﬁ-
cacy, safety and adherence to treatment.
The present study evaluated treatment used and the proﬁle
of  45 patients with PCM diagnosis. We conducted a retro-
spective, epidemiological, quantitative, cross-sectional and
observational  study through analysis of data from medical
records  of 45 patients diagnosed with PCM. We found a patient
proﬁle  very similar to that described in the literature, i.e.,
adult  men  (77.7%), aging 51.5 years.2 Regarding occupational
activity, as in other studies, patients were mostly farmers
(57.7%) or civil construction workers (11.1%).2 Three treat-
ments  evaluated were:  trimoxazole {1600 + 800 mg/day} (SXT),
amphotericin  B {1 mg/kg/day} followed by trimoxazole for
maintenance  {1600 + 800 mg/day} (SXT + ANPH), and itracona-
zole  {200 mg/day} (ITZ). To compare the treatments efﬁcacy,
each  drug regimen was  associated with clinical improve-
ment  (in days) deﬁned as the absence of signs and symptoms
and  overall treatment time (in months) deﬁned as a nega-
tive  serology. The mean time to clinical improvement showed
no  difference between the three tested treatments (p = 0.714).
Table  1 shows the results.
Regarding the overall treatment time, the group treated
with  SXT ﬁnished treatment with medical discharge in 15.2
months.  For the ANPH + SXT group, mean time was 13.3
Table 1 – Mean time (in days) for clinical improvement of
patients  with PCM.
SXT ITZ ANPH + SXT
Number of patients 27 8 10
Mean 20.4 26.2 24.2
Standard deviation 15.8 15.5 28.7
1
2
3
4months and for the ITZ, was  18.4 months. The differences were
not  statistically signiﬁcant (p = 0.592).
The  mean time until seeking medical assistance was  2.13
months.  For patients related to rural activities, time was  2.3
months,  while for all others, it was  1.8 months (p = 0.65).
This  ﬁnding is supported by other authors who  reported that
residents  of rural areas have greater difﬁculty in accessing
public health services, which contributes to late diagnosis of
disease.3
Despite the consensus of the Brazilian Society of Tropical
Medicine and other studies suggesting a greater efﬁcacy of
itraconazole,  the present study, under the conditions it was
held,  did not conﬁrm this result.1,4 No difference was found
between the SXT combination, amphotericin B followed by
SXT  and ITZ with respect to signs of clinical improvement,
symptoms, and time to negative serology. Compliance rate
treatment  in non-alcoholics was  79.3%, falling to 43.7% for
frequent  users of alcohol (p = 0.02). Alcohol use was negatively
related  with treatment compliance, as was  also found in other
studies.5 The data show that treatment options outlined in
the  Brazilian Consensus for treatment of PCM, correctly used,
showed  similar results regarding clinical improvement and
overall  treatment time.
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